– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Primary central nervous system lymphoma is ...
In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma. In an interview with CURE, Dr. Lakshmi Nayak, a ...
An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas. This is ...
Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. A phase IIA clinical trial to ...
FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL. Deciphera Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a new ...
The family of Bung Siriboon, who vanished 15 years ago while walking to school, now face a new heartbreaking challenge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results